National
Murphy confident Congress will overturn ‘Don’t Ask’ this year
The sponsor of “Don’t Ask, Don’t Tell” repeal legislation in the U.S. House is confident Congress will overturn the law this year — even as other lawmakers have indicated repeal may not happen until later.
In an interview with DC Agenda Tuesday, Rep. Patrick Murphy (D-Pa.) said he believed lawmakers would overturn this year the 1993 statute preventing gays, lesbians and bisexuals from serving openly in the U.S. military and that he’s expecting Congress to take up the issue “legislatively in the next couple months.”
Murphy said the upcoming defense authorization bill could be a vehicle for passing repeal legislation. He noted that passage as part of defense authorization would give the Pentagon time to complete the study currently underway on the law.
“We usually don’t pass that into law until October of that year,” Murphy said. “October is about seven months away. That’s plenty of time for the folks to get ready to just put out to the troops that you need to respect not just one another’s race, one another creed, but also one another’s sexual orientation.”
Still, Murphy said defense authorization was just one way that Congress could enact repeal. Other options remain available.
“I think that’s one of the vehicles moving forward, and so I anticipate getting this done this year,” he said.
Murphy said momentum has been building toward repeal in the last couple months, leading to a position where Congress can overturn the 1993 law. In particular, Murphy cited the testimony Defense Secretary Robert Gates and Chairman of the Joint Chiefs of Staff Adm. Michael Mullen gave last month in support of ending “Don’t Ask, Don’t Tell.”
“Now is the time when senior leadership in our military who are responsible to have the best policies for our young men and women who serve the country are calling for the repeal of ‘Don’t Ask, Don’t Tell’ — as has our commander-in-chief,” Murphy said. “So now Congress needs to get off the sidelines and get this done this year.”
Murphy said the growing number of lawmakers who have expressed support for repeal also is contributing to the momentum.
Last month, Murphy picked up another co-sponsor for repeal legislation in the House, Rep. Peter Visclosky (D-Ind.), bringing the total number of co-sponsors for the Military Readiness Enhancement Act to 188. Murphy said he’s received commitments from about two dozen other House members that they’d vote in favor of the bill should it come to a floor vote, which would bring the votes close to the 218 needed for passage.
Murphy also expressed enthusiasm for plans by Sen. Joseph Lieberman (I-Conn.) to soon introduce companion legislation in the Senate and said the independent senator should be able to bring Democrats and Republicans on board.
“I know he’s committed to repealing ‘Don’t Ask, Don’t Tell,’“ Murphy said. “I know he knows the best thing for our military, and frankly, when it comes to foreign policy, I think he’s been one of the leaders in the Senate.”
Murphy said he’s expecting Lieberman’s bill to be similar to his in terms of doing away with “Don’t Ask, Don’t Tell” and providing for a non-discrimination policy. But Murphy said he’s unsure about other details, such as whether Lieberman’s bill will have a longer implementation time to allow the Pentagon to complete its study on the law.
The lawmaker is not alone in expecting that Congress will repeal “Don’t Ask, Don’t Tell” this year. On Saturday, Joe Solmonese, president of the Human Rights Campaign, said at a fundraising dinner in Raleigh, N.C., that 2010 would be the year that advocates would do away with the ban on open service in the military.
Despite these expectations, others have expressed doubt about whether Congress will repeal “Don’t Ask, Don’t Tell” this year.
Media reports have indicated the White House hasn’t provided Congress a clear path forward on proceeding with repeal. Rep. Barney Frank (D-Mass.) recently told DC Agenda the White House has been “muddled” on the issue and that he’s hoping the White House makes the path clear for Congress in coming weeks.
But Murphy said the White House has been crystal clear in that Congress should work to do away with “Don’t Ask, Don’t Tell.”
“The commander-in-chief has said that he wants the Congress to put a bill on his desk to finally repeal this harmful policy that has hurt our national security and has cost the American taxpayer $1.3 billion,” Murphy said.
Another voice of doubt comes from Senate Armed Services Committee Chair Carl Levin (D-Mich.), who said he’s skeptical the votes are there to repeal the law banning open service.
Levin has been floating the idea of a legislative moratorium on discharges, which he said lawmakers might more likely support because it doesn’t predetermine the outcome of the study currently underway at the Pentagon.
But Murphy called a moratorium “half-stepping” and said that full repeal of “Don’t Ask, Don’t Tell” is still the way to go.
“This is a time when we need to make sure that we refocus our efforts on capturing or killing Osama bin Laden and al Qaeda,” Murphy said. “Now is not the time to have Chapter 15 investigations and hearing if someone is gay or straight in our military.”
Along with many other Democratic lawmakers, Murphy could face a difficult re-election campaign this fall. A number of Republicans have lined up to challenge the lawmaker, including Mike Fitzpatrick, the former House member whom Murphy ousted in 2006 by taking 50.3 percent of the vote.
Asked whether his public support for repealing “Don’t Ask, Don’t Tell” was having an impact on his constituents’ view of him, Murphy dismissed such worries about his re-election prospects.
“I wasn’t elected to worry about re-election,” he said. “I was elected to make sure that I’m fighting for the families of our military and to keep our country and our economy strong, and I’m doing everything in my power to make good on that special trust and confidence.”
A Wider Bridge on Friday announced it will shut down at the end of the month.
The group that “mobilizes the LGBTQ community to fight antisemitism and support Israel and its LGBTQ community” in a letter to supporters said financial challenges prompted the decision.
“After 15 years of building bridges between LGBTQ communities in North America and Israel, A Wider Bridge has made the difficult decision to wind down operations as of Dec. 31, 2025,” it reads.
“This decision comes after challenging financial realities despite our best efforts to secure sustainable funding. We deeply appreciate our supporters and partners who made this work possible.”
Arthur Slepian founded A Wider Bridge in 2010.
The organization in 2016 organized a reception at the National LGBTQ Task Force’s Creating Change Conference in Chicago that was to have featured to Israeli activists. More than 200 people who protested against A Wider Bridge forced the event’s cancellation.
A Wider Bridge in 2024 urged the Capital Pride Alliance and other Pride organizers to ensure Jewish people can safely participate in their events in response to an increase in antisemitic attacks after Hamas militants attacked Israel on Oct. 7, 2023.
The Jewish Telegraphic Agency reported authorities in Vermont late last year charged Ethan Felson, who was A Wider Bridge’s then-executive director, with lewd and lascivious conduct after alleged sexual misconduct against a museum employee. Rabbi Denise Eger succeeded Felson as A Wider Bridge’s interim executive director.
A Wider Bridge in June honored U.S. Rep. Debbie Wasserman Schultz (D-Fla.) at its Pride event that took place at the Capital Jewish Museum in D.C. The event took place 15 days after a gunman killed two Israeli Embassy employees — Yaron Lischinsky and Sarah Milgrim — as they were leaving an event at the museum.
“Though we are winding down, this is not a time to back down. We recognize the deep importance of our mission and work amid attacks on Jewish people and LGBTQ people – and LGBTQ Jews at the intersection,” said A Wider Bridge in its letter. “Our board members remain committed to showing up in their individual capacities to represent queer Jews across diverse spaces — and we know our partners and supporters will continue to do the same.”
Editor’s note: Washington Blade International News Editor Michael K. Lavers traveled to Israel and Palestine with A Wider Bridge in 2016.
The White House
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
President made announcement on Friday
President Donald Trump met with leaders from some of the world’s largest pharmaceutical companies at the White House on Friday to announce his new “Trump Rx” plan and outline efforts to reduce medication costs for Americans.
During the roughly 47-minute meeting in the Roosevelt Room, Trump detailed his administration’s efforts to cut prescription drug prices and make medications more affordable for U.S. patients.
“Starting next year, American drug prices will come down fast, furious, and will soon be among the lowest in the developed world,” Trump said during the meeting. “For decades, Americans have been forced to pay the highest prices in the world for prescription drugs by far … We will get the lowest price of anyone in the world.”
Trump signed an executive order in May directing his administration “to do everything in its power to slash prescription drug prices for Americans while getting other countries to pay more.”
“This represents the greatest victory for patient affordability in the history of American health care, by far, and every single American will benefit,” he added.
Several pharmaceutical executives stood behind the president during the announcement, including Sanofi CEO Paul Hudson, Novartis CEO Vas Narasimhan, Genentech CEO Ashley Magargee, Boehringer Ingelheim (USA) CEO Jean-Michel Boers, Gilead Sciences CEO Dan O’Day, Bristol Myers Squibb General Counsel Cari Gallman, GSK CEO Emma Walmsley, Merck CEO Robert Davis, and Amgen Executive Vice President Peter Griffith.
Also in attendance were Health and Human Services Secretary Robert F. Kennedy Jr., Commerce Secretary Howard Lutnick, Centers for Medicare and Medicaid Services Administrator Mehmet Oz, and Food and Drug Administration Commissioner Marty Makary.
Under the Trump Rx plan, the administration outlined a series of proposed drug price changes across multiple companies and therapeutic areas. Among them were reductions for Amgen’s cholesterol-lowering drug repatha from $573 to $239; Bristol Myers Squibb’s HIV medication reyataz from $1,449 to $217; Boehringer Ingelheim’s type 2 diabetes medication jentadueto from $525 to $55; Genentech’s flu medication xofluza from $168 to $50; and Gilead Sciences’ hepatitis C medication epclusa from $24,920 to $2,425.
Additional reductions included several GSK inhalers — such as the asthma inhaler advair diskus 500/50, from $265 to $89 — Merck’s diabetes medication januvia from $330 to $100, Novartis’ multiple sclerosis medication mayzent from $9,987 to $1,137, and Sanofi’s blood thinner plavix from $756 to $16. Sanofi insulin products would also be capped at $35 per month’s supply.
These prices, however, would only be available to patients who purchase medications directly through TrumpRx. According to the program’s website, TrumpRx “connects patients directly with the best prices, increasing transparency, and cutting out costly third-party markups.”
Kennedy spoke after Trump, thanking the president for efforts to lower pharmaceutical costs in the U.S., where evidence has shown that drug prices — including both brand-name and generic medications — are nearly 2.78 times higher than prices in comparable countries. According to the Pharmaceutical Research and Manufacturers of America, roughly half of every dollar spent on brand-name drugs goes to entities that play no role in their research, development, or manufacturing.
“This is affordability in action,” Kennedy said. “We are reversing that trend and making sure that Americans can afford to get the life-saving solutions.”
Gilead CEO Dan O’Day also spoke about how the restructuring of drug costs under TrumpRx, combined with emerging technologies, could help reduce HIV transmission — a virus that, if untreated, can progress to AIDS. The LGBTQ community remains disproportionately affected by HIV.
“Thank you, Mr. President — you and the administration,” O’Day said. “I think this objective of achieving the commitment to affordability and future innovation is extraordinary … We just recently launched a new medicine that’s only given twice a year to prevent HIV, and we’re working with Secretary Kennedy and his entire team, as well as the State Department, as a part of your strategy to support ending the epidemic during your term.
“I’ve never been more optimistic about the innovation that exists across these companies and the impact this could have on America’s health and economy,” he added.
Trump interjected, asking, “And that’s working well with HIV?”
“Yes,” O’Day replied.
“It’s a big event,” Trump said.
“It literally prevents HIV almost 100 percent given twice a year,” O’Day responded.
A similar anti-HIV medication is currently prescribed more than injectable form mentioned by O’Day. PrEP, is a medication regimen proven to significantly reduce HIV infection rates for people at high risk. Without insurance, brand-name Truvada can cost roughly $2,000 per month, while a generic version costs about $60 per month.
Even when medication prices are reduced, PrEP access carries additional costs, including clinic and laboratory fees, office visits, required HIV and sexually transmitted infection testing, adherence services and counseling, and outreach to potentially eligible patients and providers.
According to a 2022 study, the annual total cost per person for PrEP — including medication and required clinical and laboratory monitoring — is approximately $12,000 to $13,000 per year.
The TrumpRx federal platform website is now live at TrumpRx.gov, but the program is not slated to begin offering reduced drug prices until January.
The White House
EXCLUSIVE: Democracy Forward files FOIA lawsuit after HHS deadnames Rachel Levine
Trans former assistant health secretary’s name changed on official portrait
Democracy Forward, a national legal organization that works to advance democracy and social progress through litigation, policy and public education, and regulatory engagement, filed a lawsuit Friday in federal court seeking to compel the U.S. Department of Health and Human Services to release information related to the alteration of former Assistant Secretary for Health Adm. Rachel Levine’s official portrait caption.
The lawsuit comes in response to the slow pace of HHS’s handling of multiple Freedom of Information Act requests — requests that federal law requires agencies to respond to within 20 working days. While responses can take longer due to backlogs, high request volumes, or the need for extensive searches or consultations, Democracy Forward says HHS has failed to provide any substantive response.
Democracy Forward’s four unanswered FOIA requests, and the subsequent lawsuit against HHS, come days after someone in the Trump-Vance administration changed Levine’s official portrait in the Hubert H. Humphrey Building to display her deadname — the name she used before transitioning and has not used since 2011.
According to Democracy Forward, HHS “refused to release any records related to its morally wrong and offensive effort to alter former Assistant Secretary for Health Admiral Rachel Levine’s official portrait caption.” Levine was the highest-ranking openly transgender government official in U.S. history and served as assistant secretary for health and as an admiral in the U.S. Public Health Service Commissioned Corps from 2021 to 2025.
Democracy Forward President Skye Perryman spoke about the need to hold the Trump-Vance administration accountable for every official action, especially those that harm some of the most targeted Americans, including trans people.
“The question every American should be asking remains: what is the Trump-Vance administration hiding? For an administration that touts its anti-transgender animus and behavior so publicly, its stonewalling and silence when it comes to the people’s right to see public records about who was behind this decision is deafening,” Perryman said.
“The government’s obligation of transparency doesn’t disappear because the information sought relates to a trailblazing former federal official who is transgender. It’s not complicated — the public is entitled to know who is making decisions — especially decisions that seek to alter facts and reality, erase the identity of a person, and affect the nation’s commitment to civil rights and human dignity.”
“HHS’s refusal to respond to these lawful requests raises more serious concerns about transparency and accountability,” Perryman added. “The public has every right to demand answers — to know who is behind this hateful act — and we are going to court to get them.”
The lawsuit also raises questions about whether the alteration violated federal accuracy and privacy requirements governing Levine’s name, and whether the agency improperly classified the change as an “excepted activity” during a lapse in appropriations. By failing to make any determination or produce any records, Democracy Forward argues, HHS has violated its obligations under federal law.
The case, Democracy Forward Foundation v. U.S. Department of Health and Human Services, was filed in the U.S. District Court for the District of Columbia. The legal team includes Anisha Hindocha, Daniel McGrath, and Robin Thurston.
The Washington Blade reached out to HHS, but has not received any comment.
The lawsuit and four FOIA requests are below:
A Wider Bridge to close
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
Rehoboth’s Blue Moon is for sale but owners aim to keep it in gay-friendly hands
Comings & Goings
Advocates say MTG bill threatens trans youth, families, and doctors
LGBTQ Democrats say they’re ready to fight to win in 2026
Brian Footer suspends campaign for Ward 1 D.C. Council seat
Far-right José Antonio Kast elected Chile’s next president
Lighting candles in a time of exhaustion
In real estate, trust the process
-
Politics3 days agoLGBTQ Democrats say they’re ready to fight to win in 2026
-
District of Columbia2 days ago
Brian Footer suspends campaign for Ward 1 D.C. Council seat
-
Chile5 days ago
Far-right José Antonio Kast elected Chile’s next president
-
Opinions3 days ago
Lighting candles in a time of exhaustion
